Related Experiment Video
Updated: Jan 28, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway
Jian Zhou1, Guimei Qu2, Ge Zhang1
1Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Background:
Drug resistance is common in cancer chemotherapy. This study investigates the role of Glycerol kinase 5 (GK5) in mediating gefitinib resistance in NSCLC.
Methods:
The exosomal mRNA of GK5 was detected using a tethered cationic lipoplex nanoparticle (TCLN) biochip. Real-time PCR and Western blot were used to examine the expression of GK5 mRNA and protein in gefitinib-sensitive and -resistant human lung adenocarcinoma cells. The cell counting kit-8, EdU assay, flow cytometry, and JC-1 dye were used to measure cell proliferation, cell cycle, and the mitochondrial membrane potential.
Results:
We found that the exosomal mRNA of GK5 in the plasma of patients with gefitinib-resistant adenocarcinoma was significantly higher compared with that of gefitinib-sensitive patients. The mRNA and protein levels of GK5 were significantly upregulated in gefitinib-resistant human lung adenocarcinoma PC9R and H1975 cells compared with gefitinib-sensitive PC9 cells. Silencing GK5 in PC9R cells induced mitochondrial damage, caspase activation, cell cycle arrest, and apoptosis via SREBP1/SCD1 signaling pathway.
Conclusions:
We demonstrated that GK5 confers gefitinib resistance in lung cancer by inhibiting apoptosis and cell cycle arrest. GK5 could be a novel therapeutic target for treatment of NSCLC with resistance to EGFR tyrosine kinase inhibitors.
Insights
Glycerol kinase 5 (GK5) drives gefitinib resistance in non-small cell lung cancer (NSCLC) by blocking apoptosis and cell cycle arrest. Targeting GK5 may overcome resistance to EGFR tyrosine kinase inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Drug resistance is a significant challenge in cancer chemotherapy.
- Glycerol kinase 5 (GK5) is investigated for its role in mediating gefitinib resistance in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To investigate the role of GK5 in gefitinib resistance in NSCLC.
- To explore GK5 as a potential therapeutic target for overcoming resistance to EGFR tyrosine kinase inhibitors.
Main Methods:
- Exosomal GK5 mRNA detection using a tethered cationic lipoplex nanoparticle (TCLN) biochip.
- Real-time PCR and Western blot to assess GK5 expression.
- Cell proliferation, cell cycle, and mitochondrial membrane potential assays (CCK-8, EdU, flow cytometry, JC-1).
Main Results:
- Elevated exosomal GK5 mRNA in plasma of gefitinib-resistant NSCLC patients.
- Upregulated GK5 mRNA and protein in gefitinib-resistant cell lines (PC9R, H1975) compared to sensitive cells (PC9).
- GK5 silencing in PC9R cells induced mitochondrial damage, caspase activation, cell cycle arrest, and apoptosis via the SREBP1/SCD1 pathway.
Conclusions:
- GK5 confers gefitinib resistance in lung cancer by inhibiting apoptosis and cell cycle arrest.
- GK5 represents a novel therapeutic target for NSCLC resistant to EGFR tyrosine kinase inhibitors.
More Related Videos
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Non-Canonical Wnt Signaling Pathways

